Anti-CD38-based quadruplet versus triplet induction regimens in transplant-ineligible newly diagnosed multiple myeloma: a systematic review and meta-analysis.

Grace Lau, Madhu Bhargavi Chandra, Henri Fero, Fahad Alabbas

Abstract readSystematic ReviewMeta-AnalysisComparative Study

In one paragraph

Synthesis in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Grace LauDivision of Haematology, Department of Medicine, Princess Margaret Hospital, Hong Kong, China. gracewnlau@cuhk.edu.hk.ORCID http://orcid.org/0000-0002-1812-0639

Madhu Bhargavi ChandraWellstar Health System, Marietta, United States.

Henri FeroDivision of Critical Care, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Canada.

Fahad AlabbasDepartment of Haematology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis systematic review and meta-analysis compared the efficacy and safety of anti-CD38-containing quadruplet and triplet regimens in transplant-ineligible patients with newly diagnosed multiple myeloma (TIE-NDMM).

methodsA comprehensive literature search was conducted across PubMed, Embase, and Cochrane databases up to April 30, 2025. Randomized controlled trials (RCTs) comparing anti-CD38-based quadruplet and triplet regimens were analysed for outcomes including efficacy and toxicity.

resultsSix RCTs with 2089 patients were included. Quadruplet regimens yielded significantly greater PFS (HR 0.49, 95% CI: 0.39-0.61; P < 0.00001, I

conclusionAnti-CD38-based quadruplet regimens are superior to triplet regimens for non-frail TIE-NDMM patients, improving key efficacy outcomes with manageable safety concerns.

Indexed as

ADP-ribosyl Cyclase 1Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsInduction ChemotherapyMembrane GlycoproteinsMultiple MyelomaHumansRandomized Controlled Trials as TopicTreatment OutcomeADP-ribosyl Cyclase 1Antibodies, MonoclonalCD38 protein, humanMembrane GlycoproteinsAnti-CD38Multiple myelomaQuadrupletsTransplant-ineligible

Identifiers

PMID41928036

DOI10.1007/s12185-026-04195-1

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.